Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 11, 2023

Rituximab vs Ocrelizumab in Patients With Relapsing–Remitting MS

JAMA Neurology


Additional Info

JAMA Neurology
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 2023 Jun 12;[EPub Ahead of Print], I Roos, S Hughes, G McDonnell, CB Malpas, S Sharmin, C Boz, R Alroughani, S Ozakbas, K Buzzard, O Skibina, A van der Walt, H Butzkueven, J Lechner-Scott, J Kuhle, M Terzi, G Laureys, L Van Hijfte, N John, P Grammond, F Grand'Maison, A Soysal, AV Jensen, PV Rasmussen, KB Svendsen, I Barzinji, HH Nielsen, T Sejbæk, S Prakash, MLM Stilund, A Weglewski, NM Issa, M Kant, F Sellebjerg, O Gray, M Magyari, T Kalincik

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading